A Patient with TP53 Germline Mutation Developed Bowen's Disease and Myelodysplastic Syndrome with Myelofibrosis after Chemotherapy against Ovarian Cancer

DOI Web Site Web Site PubMed 2 Citations 40 References

Bibliographic Information

Other Title
  • Patient with TP53 Germline Mutation Developed Bowen s Disease and Myelodysplastic Syndrome with Myelofibrosis after Chemotherapy against Ovarian Cancer

Search this article

Abstract

Here we report a case of myelodysplastic syndrome (MDS) with myelofibrosis associated with Bowen’s disease. A female patient had undergone an operation and chemotherapy for ovarian cancer when she was 65 years old, and she developed MDS at the age of 70 years old. PCR-single strand conformation polymorphism (SSCP) analysis of peripheral blood mononuclear cells, a Bowen’s disease lesion, and normal skin showed an abnormal peak in TP53 exon5. Direct sequencing revealed that they all had missense mutation in codon 175 (G to A) of arginine switched to histidine, suggesting a germline mutation of TP53. It was speculated that p53 function was lost by TP53 germline mutation with the loss of a wild type allele induced by the chemotherapy against ovarian cancer, leading to the development of MDS. No therapeutic effects of low dose melphalan or cyclosporine A on MDS were observed, however one month of 30 mg/day prednisolone administration induced a hematological response.

Journal

  • Internal Medicine

    Internal Medicine 44 (5), 490-495, 2005

    The Japanese Society of Internal Medicine

Citations (2)*help

See more

References(40)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top